Preferred Label : SHP2 Inhibitor BBP-398;
NCIt definition : An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor
type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic
activity. Upon oral administration, SHP2 inhibitor BBP-398 targets, allosterically
binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling,
inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2,
an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival,
differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling
pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific
mutations and rearrangements which are dependent on SHP2 for their oncogenic signaling.
SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and
is involved in immune checkpoint modulation.;
Molecule name : BBP-398; IACS-15509; IACS 15509; BBP 398; BMS-986466; BMS 986466;
NCI Metathesaurus CUI : CL1643294;
Origin ID : C177417;
UMLS CUI : C5447751;
Semantic type(s)
- concept_is_in_subset
- has_target
